{"id":1063434,"date":"2013-02-03T07:58:20","date_gmt":"2013-02-03T07:58:20","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/ioms-shapiro-wants-to-see-more-changes-from-california-stem-cell-agency\/"},"modified":"2024-08-17T20:29:30","modified_gmt":"2024-08-18T00:29:30","slug":"ioms-shapiro-wants-to-see-more-changes-from-california-stem-cell-agency-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/ioms-shapiro-wants-to-see-more-changes-from-california-stem-cell-agency-2.php","title":{"rendered":"IOM's Shapiro Wants to See More Changes from California Stem Cell Agency"},"content":{"rendered":"

Additional mainstream media news
coverage surfaced last Friday involving the California stem cell
agency's response to the blue-ribbon report from the Institute of
Medicine(IOM)<\/b>, whose concerns about the agency ranged from conflicts of interest to grant
appeals by rejected researchers.<\/p>

<\/div>
One of the more interesting pieces was
done by Stephanie O'Neill<\/b> of Los Angeles radio station KPCC<\/b>. To her
credit, she contacted the chairman of the IOM panel, Harold Shapiro<\/b>,
for his fresh take on what the stem cell agency's board did on
Wednesday.<\/div>
<\/div>
His comments were somewhat different
than those read Wednesday at the CIRM board meeting. On Friday, Shapiro was quoted as
saying the board action was “an important first step forward,”
but he added a caveat. O'Neill wrote,<\/div>

“'I’m encouraged by this,' Shapiro
told KPCC. 'Presumably in the future they’ll take other steps. But
these are steps they could take without any legislative approval and
…I think it does respond in a pretty significant way to the spirit
of the report.'
“But Shapiro expressed concern that
the agency is making only 'small moves' to address a recommendation
that CIRM separate operations from oversight. Currently, the ICOC
functions 'both as an executor and as an overseer—competing duties
that compromise the ICOC’s critical role of providing independent
oversight and strategic direction,' according to the December IOM
report.
“'But  I do understand… that
would be a move that they would have to take over time so we’ll
have to wait and see,' Shapiro said.
“Thomas agreed and said that while
CIRMs recommendations more clearly define the roles of chairman and
president, more refinements will be likely over time.”<\/p><\/blockquote>

From the Los Angeles Times<\/b>, came a
piece from Eryn Brown<\/b>. Her article was brief<\/a> and she referred her
readers to the California Stem Cell Report<\/b> for details. Her first
paragraph said,<\/div>

“Changes may be on the way at
California’s stem cell funding agency.”<\/p><\/blockquote>

In coverage outside the mainstream media,
the Burrill Report<\/b> carried an article by Daniel Levine<\/b>. The Burrill
Report is produced by Burrill & Co<\/b>., a San Francisco life
sciences financial firm. Levine's straight-forward account<\/a> was
largely based on the CIRM press release and the IOM report.<\/div>
<\/div>
<\/div>
Two bloggers surfaced with some
coverage. UC Davis<\/b> stem cell researcher Paul Knoepfler<\/b>, who is a CIRM
grantee, called the Thomas plan a “bold one-year experiment” <\/a> and
“biggest development for CIRM in many years.” Knoepfler said,<\/div>

“I’m still not sure I’m a fan of
all of the proposed changes, but I would say the plan is bold and
creative.”<\/p><\/blockquote>

On livingbiology.com<\/b>, an unidentified
CIRM grantee carried a few brief items<\/a> live from the meeting.<\/div>

Source:
http:\/\/feedproxy.google.com\/~r\/blogspot\/uqpFc\/~3\/A2ayEbm2Se0\/ioms-shapiro-wants-to-see-more-changes.html<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Additional mainstream media newscoverage surfaced last Friday involving the California stem cellagency's response to the blue-ribbon report from the Institute ofMedicine(IOM), whose concerns about the agency ranged from conflicts of interest to grantappeals by rejected researchers.One of the more interesting … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25,1246878],"tags":[],"class_list":["post-1063434","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy","category-stem-cells"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063434"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1063434"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063434\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1063434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1063434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1063434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}